Corticosteroid Nasal Spray in COVID-19 Anosmia

• Status: Completed
• Trial end date: 2020-11-03
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the role of the topical corticosteroids nasal spray (mometasone furoate nasal spray) in improving anosmia in patients recovered from COVID-19 infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Treatments: Mometasone Furoate

Criteria

Inclusion Criteria:

• adults 18 yrs or older patients

• confirmed case (+ve PCR),

• recovered/discharged (2 -ve PCR),

• suffered from sudden recent anosmia or hyposmia

Exclusion Criteria:

• patients already on nasal steroid

• with previous chronic rhinological pathologies,

• patients on systemic steroid for previous systemic disease,

• anosmia improved before COVID19 recovery,

• pregnancy

• patients who will not complete the follow up period.